Theravectys makes two appointments
This article was originally published in Scrip
Theravectys, a French biotechnology company specializing in the development of vaccines based on lentiviral vector technology, has named Paul Gineste head of clinical development and Pierre d'Epenoux head of strategy and business development. Mr Gineste joins the Paris-based firm from AB Science where he was director of clinical studies. Meanwhile, Mr d'Epenoux was formerly vice-president of strategy and business development at Sanofi. They will both report to Theravectys CEO Renaud Valliant.